Latest Biotech News

Regenxbio shares fell sharply after investors reacted to guidance that the FDA may require a randomized controlled trial for its DMD gene therapy candidate RGX-202, despite positive pivotal phase...

Telitacicept, developed by RemeGen, showed a significant reduction in proteinuria in a prespecified interim analysis of a phase 3 trial in high-risk IgA nephropathy patients. In NEJM-published...

JPMorgan’s Q1 2026 biopharma licensing and venture report shows dealmaking momentum alongside tighter risk tolerance, with licensing value rising even as venture funding for early-stage companies...

Researchers presenting at ESTRO 2026 reported a new approach to guide treatment in advanced cancer using circulating tumor DNA (ctDNA) detected in blood plasma. The work positions ctDNA as a...

A study presented at ESTRO 2026 in Stockholm found that prostate cancer radiotherapy delivered in two larger doses over eight days was as safe and effective as a conventional five-fraction...

Researchers at ESTRO 2026 reported targeted stereotactic body radiotherapy (SBRT) data for oligometastatic breast cancer, indicating potential for extending control and progression-free survival...

An international clinical trial reported improved radiotherapy planning performance using AI for cervical and prostate cancer treatment, with investigators from University College London (UCL) and...

Biotech and pharma teams are increasingly turning to strategic outsourcing to capture more value from mature products as patent cliffs loom and internal resources face pressure. An analysis...

Regeneron’s LAG-3 inhibitor missed its primary endpoint in a phase 3 melanoma trial, failing to beat Merck’s Keytruda in the study readout. Analysts cited the result as the second late-stage...

Regenxbio’s RGX-202 generated positive pivotal phase 3 data for Duchenne muscular dystrophy, but investors reacted negatively after the FDA recommended the company run a randomized controlled...

RemeGen’s telitacicept delivered a stronger reduction in proteinuria than placebo in a prespecified interim analysis of a phase 3 trial in high-risk IgA nephropathy. In patients with persistent...

Researchers presented an approach using circulating tumor DNA (ctDNA) detected in blood plasma to tailor radiotherapy and treatment decisions for patients with oligometastatic cancers. The...

An international clinical trial led by University College London (UCL) and the London School of Hygiene & Tropical Medicine (LSHTM) reported that AI can improve radiotherapy treatment planning for...

New findings presented at ESTRO 2026 in Stockholm reported that a prostate cancer radiotherapy regimen delivered in two larger sessions over eight days can be as safe and effective as the...

Researchers at ESTRO 2026 presented evidence that targeted stereotactic body radiotherapy (SBRT) can extend control in early-stage breast cancer that has begun to spread, described as...

Startup Durabilityte is positioning implantable engineered cell “factories” as a way to produce therapeutic proteins inside the body, aiming to bypass parts of conventional biologics...

JPMorgan’s Q1 2026 Biopharma Licensing and Venture report said licensing and M&A activity is accelerating, even as venture capital remains selective and risk-averse. The bank reported biopharma...

A study in Nature Communications linked dyskerin pseudouridine synthase 1 (DKC1) to colorectal cancer progression, describing how the protein disrupts sphingolipid biosynthesis to support tumor...

RemeGen’s telitacicept produced a large proteinuria reduction in a prespecified interim analysis of its Phase 3 TELIGAN program in high-risk IgA nephropathy, according to results published in...

Regenxbio’s RGX-202 delivered positive pivotal Phase 3 data in Duchenne muscular dystrophy, but investors punished the stock after the company disclosed the FDA recommended a randomized controlled...